Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION-1: RYZ101 vs Standard of Care in Advanced GEP-NETs
NCT05477576Phase 3Active, not recruiting
- Sponsor
- RayzeBio
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 8
01
Overview
A Phase 3 trial of actinium-225 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by RayzeBio. Started Mar 2022; status: active, not recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05477576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477576.